[1] |
Mungan MU, Canda AE, Tuzel E, et al. Risk factors for mucosal prostatic urethral involvement in superficial transitional cell carcinoma of the bladder[J]. Euro Urol, 2005, 48(5): 760-763.
|
[2] |
陈庆生. 原发性前列腺尿路上皮癌2例报道并文献复习[J]. 临床医药实践, 2013, 10(3): 181-184.
|
[3] |
包佑根, 王金根, 毛允义,等. 前列腺尿路上皮癌4例分析[J]. 江西医药, 2017, 52(6): 49-51.
|
[4] |
杨斌, 王国良, 贺慧颖. 巢状变异型尿路上皮癌的病理与诊治进展[J]. 中华泌尿外科杂志, 2017, 38(2): 155-157.
|
[5] |
Oh WJ, Chung AM, Kim JS, et al. Differential immunohistochemical profiles for distinguishing prostate carcinoma and urothelial carcinoma[J]. J Pathol Transl Med, 2016, 50(5): 345-354.
|
[6] |
Liedberg F, Chebil G, MaNsson W. Urothelial carcinoma in the prostatic urethra and prostate: current controversies[J]. Expert Rev of Anticancer Ther, 2007, 7(3): 383-390.
|
[7] |
Hardeman SW, Perry A, Soloway MS. Transitional cell carcinoma of the prostate following intravesical therapy for transitional cell carcinoma of the bladder[J]. J Urol, 1988, 140(2): 289-292.
|
[8] |
Cui J, Wang W, Chen S, et al. Combination of intravesical chemotherapy and bacillus calmette-guerin versus bacillus calmette-guerin monotherapy in intermediate- and high-risk nonmuscle invasive bladder cancer: a systematic review and meta-analysis[J]. Medicine, 2016, 95(3): e2572.
|
[9] |
Hamasaki T, Kondo Y, Ogata Y, et al. Advanced carcinoma of the prostatic urethra in a patient with marked response to chemotherapy, leading to preservation of the bladder[J]. Int J Clin Oncol, 2010, 15(1): 109-111.
|
[10] |
詹运运, 孙毅伦, 蒋敏,等. 原发性前列腺尿路上皮癌1例并文献复习[J]. 蚌埠医学院学报, 2015, 40(12): 1697-1698.
|
[11] |
Angulo J C, Núñez C, Gonzalez J, et al. Primary transitional cell carcinoma of the prostate: a male disease with dismal prognosis despite cisplatin-based systemic chemotherapy[J]. J Men's Health, 2010, 7(1): 64-72.
|
[12] |
Ichihara K, Masumori N, Kitamura H, et al. Clinical outcomes of urothelial carcinoma of the prostate detected in radical cystectomy specimens[J]. Int J Clin Oncol, 2014, 19(1): 152-156.
|